BlackRock
RNTX

BlackRock’s Rein Therapeutics RNTX Stock Holding History

BlackRock’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.1K Buy
68,528
+13,522
+25% +$16.8K ﹤0.01% 4985
2025
Q4 		$63.8K Buy
55,006
+2,132
+4% +$2.94K ﹤0.01% 4998
2025
Q3 		$60.5K Buy
52,874
+1,438
+3% +$1.83K ﹤0.01% 4944
2025
Q2 		$72K Buy
51,436
+133
+0.3% +$239 ﹤0.01% 4913
2025
Q1 		$90.8K Sell
51,303
-27,650
-35% -$58K ﹤0.01% 4791
2024
Q4 		$182K Buy
78,953
+27,673
+54% +$83.8K ﹤0.01% 4640
2024
Q3 		$182K Buy
51,280
+19,995
+64% +$53.4K ﹤0.01% 4545
2024
Q2 		$86.7K Buy
+31,285
New +$129K ﹤0.01% 4736
2024
Q1 		– Sell
-189
Closed -$576 – 5413
2023
Q4 		$576 Hold
189
– – ﹤0.01% 5283
2023
Q3 		$287 Hold
189
– – ﹤0.01% 5373
2023
Q2 		$338 Hold
189
– – ﹤0.01% 5439
2023
Q1 		$234 Hold
189
– – ﹤0.01% 5512
2022
Q4 		$448 Sell
189
-1
-0.5% -$3 ﹤0.01% 5670
2022
Q3 		$1K Hold
190
– – ﹤0.01% 5775
2022
Q2 		$1K Sell
190
-9,520
-98% -$87.4K ﹤0.01% 5826
2022
Q1 		$100K Sell
9,710
-464
-5% -$4.2K ﹤0.01% 5286
2021
Q4 		$114K Buy
10,174
+448
+5% +$6.93K ﹤0.01% 5233
2021
Q3 		$198K Sell
9,726
-207
-2% -$4.54K ﹤0.01% 4994
2021
Q2 		$249K Buy
+9,933
New +$248K ﹤0.01% 4852
2020
Q2 		– Sell
-2,322
Closed -$15K – 5161
2020
Q1 		$15K Sell
2,322
-628
-21% -$7.56K ﹤0.01% 4662
2019
Q4 		$34K Sell
2,950
-32
-1% -$316 ﹤0.01% 4591
2019
Q3 		$40K Buy
2,982
+508
+21% +$7.03K ﹤0.01% 4567
2019
Q2 		$36K Buy
2,474
+1,589
+180% +$41.7K ﹤0.01% 4624
2019
Q1 		$35K Sell
885
-54
-6% -$1.68K ﹤0.01% 4528
2018
Q4 		$16K Buy
939
+85
+10% +$3.42K ﹤0.01% 4611
2018
Q3 		$47K Buy
854
+35
+4% +$2.35K ﹤0.01% 4550
2018
Q2 		$88K Sell
819
-10,979
-93% -$1.24M ﹤0.01% 4479
2018
Q1 		$1.92M Sell
11,798
-78
-0.7% -$13.9K ﹤0.01% 3687
2017
Q4 		$2.5M Buy
11,876
+56
+0.5% +$13.4K ﹤0.01% 3628
2017
Q3 		$3.16M Buy
+11,820
New +$2.96M ﹤0.01% 3596

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

BlackRock's RNTX Position: Q1 2026 in Review

BlackRock increased its Rein Therapeutics (RNTX) stake by 25% in Q1 2026, buying an estimated $16.8K and bringing the position to 68,528 shares worth $89.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4985.

BlackRock first reported a position in RNTX in Q3 2017 and has held it in 30 quarters since. The position peaked at $3.16M in Q3 2017. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • BlackRock held 68,528 shares of Rein Therapeutics worth $89.1K as of Q1 2026.
  • BlackRock bought 13,522 Rein Therapeutics shares in Q1 2026, an estimated $16.8K.
  • Rein Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4985 holding.
  • BlackRock first reported a position in Rein Therapeutics in Q3 2017 and has held it in 30 quarters since.
  • BlackRock's Rein Therapeutics position peaked at $3.16M in Q3 2017.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.